Clinical trial · Observational
Procalcitonin as a Marker for the Length of Antibiotic Treatment in Peritonitis and Intra-abdominal Infections
Etude Prospective Sur l'Impact de l'Utilisation de la Procalcitonine Dans l'évaluation de la Poursuite ou de l'arrêt du Traitement Antibiotique Empirique Lors de péritonites et d'Infections Intra-abdominales
NCT01155739CI-TRIAL-00016391completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Procalcitonin level used for determining length of antibiotic treatment in peritonitis and intra-abdominal infections. Hypothesis is that length of antibiotic use can be shortened by this method.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Secondary or Tertiary Peritonitis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- procalcitonine monitoring
- description
- PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
- label
- control group
- description
- control group: antibiotic use and length of treatment as defined by guidelines
Primary outcomes (1)
- measure
- antibiotic treatment length, hospitalisation length without antibiotic, infection recurrence, antibiotic cost
- timeFrame
- at one month and during hospital stay
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * More than 18 yo * Patient requiring surgery for peritonitis or intra-abdominal infection following: perforation, necrosis, previous operation... * Mannheim Peritonitis score \> 14 * SIRS present * Probability of survival \> 72h * Informed consent by patient/relatives Exclusion Criteria: * No SIRS * Long date corticoid treatment * Immunosuppression * Thyroid medullary carcinoma * Anaphylactic shock * Acute hepatic deficiency
References
Publications (0)
Data not yet available
No reference posted for this study.